Originally published as JCO Early Release 10.1200/JCO.2005.01.4092 on November 21 2005

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nuver, J. Articles by Gietema, J. A. Search for Related Content PubMed PubMed Citation Articles by Nuver, J. Articles by Gietema, J. A. Related Articles Related Editorial Social Bookmarking                            What's this?

Acute Chemotherapy-Induced Cardiovascular Changes in Patients With Testicular Cancer

From the Departments of Medical Oncology, Vascular Medicine, Hematology, Cardiology, and Surgical Oncology, University of Groningen and University Medical Center Groningen, Groningen, the Netherlands

Address reprint requests to J.A. Gietema, MD, PhD, Department of Medical Oncology, University Medical Center Groningen, Hanzeplein 1, P.O. Box 30.001, 9700 RB Groningen, the Netherlands; e-mail: j.a.gietema{at}int.umcg.nl

PURPOSE: After cisplatin- and bleomycin-containing chemotherapy for testicular cancer, part of the patient population will develop acute or long-term cardiovascular toxicity. It is largely unknown whether standard tests can be used to assess chemotherapy-induced cardiovascular changes.

PATIENTS AND METHODS: In 65 testicular cancer patients (median age, 27 years; range, 18 to 48 years), we measured the following cardiovascular parameters before and within 10 weeks after completion of cisplatin-based chemotherapy: platelet numbers, plasma levels of hemostatic and fibrinolytic factors, 24-hour ambulatory blood pressure, baroreflex sensitivity, intima-media thickness of the common carotid artery, and flow-mediated vasodilation of the brachial artery.

RESULTS: Compared with prechemotherapy values, the intima-media thickness of the carotid artery and plasma von Willebrand factor levels increased significantly after treatment. Platelet numbers and plasma levels of other hemostatic and fibrinolytic factors did not appear to change significantly. Blood pressure decreased significantly, but flow-mediated vasodilation and baroreflex sensitivity did not change.

CONCLUSION: In testicular cancer patients treated with cisplatin-based chemotherapy, we found an increase in plasma von Willebrand factor levels and in the intima-media thickness of the carotid artery. These changes may indicate chemotherapy-induced vascular damage and be of prognostic significance for the development of cardiovascular complications in the long term.

Supported by Grant No. RUG2000-2177 from the Dutch Cancer Society.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Editorial

• Mechanisms of Late Cardiovascular Toxicity From Cancer Chemotherapy
  Richard Steingart
  JCO 2005 23: 9051-9052 [Full Text]

This article has been cited by other articles:

				N. Starling, S. Rao, D. Cunningham, T. Iveson, M. Nicolson, F. Coxon, G. Middleton, F. Daniel, J. Oates, and A. R. Norman Thromboembolism in Patients With Advanced Gastroesophageal Cancer Treated With Anthracycline, Platinum, and Fluoropyrimidine Combination Chemotherapy: A Report From the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group J. Clin. Oncol., August 10, 2009; 27(23): 3786 - 3793. [Abstract] [Full Text] [PDF]

				P. Albers, R. Siener, S. Krege, H.-U. Schmelz, K.-P. Dieckmann, A. Heidenreich, P. Kwasny, M. Pechoel, J. Lehmann, S. Kliesch, et al. Randomized Phase III Trial Comparing Retroperitoneal Lymph Node Dissection With One Course of Bleomycin and Etoposide Plus Cisplatin Chemotherapy in the Adjuvant Treatment of Clinical Stage I Nonseminomatous Testicular Germ Cell Tumors: AUO Trial AH 01/94 by the German Testicular Cancer Study Group J. Clin. Oncol., June 20, 2008; 26(18): 2966 - 2972. [Abstract] [Full Text] [PDF]

				D. R. Feldman, G. J. Bosl, J. Sheinfeld, and R. J. Motzer Medical Treatment of Advanced Testicular Cancer JAMA, February 13, 2008; 299(6): 672 - 684. [Abstract] [Full Text] [PDF]

				A. A. Khorana, H. A. Liebman, R. H. White, T. Wun, and G. H. Lyman The Risk of Venous Thromboembolism in Patients with Cancer ASCO Educational Book, January 1, 2008; 2008(1): 240 - 248. [Abstract] [Full Text] [PDF]

				R. de Wit Refining the Optimal Chemotherapy Regimen in Good Prognosis Germ Cell Cancer: Interpretation of the Current Body of Knowledge J. Clin. Oncol., October 1, 2007; 25(28): 4346 - 4349. [Full Text] [PDF]

				S. D. Fossa, E. Gilbert, G. M. Dores, J. Chen, K. A. McGlynn, S. Schonfeld, H. Storm, P. Hall, E. Holowaty, A. Andersen, et al. Noncancer Causes of Death in Survivors of Testicular Cancer J Natl Cancer Inst, April 4, 2007; 99(7): 533 - 544. [Abstract] [Full Text] [PDF]

				D. S. Kaufman, M. A. Saksena, R. H. Young, and S. Tabatabaei Case 6-2007 -- A 28-Year-Old Man with a Mass in the Testis N. Engl. J. Med., February 22, 2007; 356(8): 842 - 849. [Full Text] [PDF]

				H. Haugnes, N Aass, S. Fossa, O Dahl, O Klepp, E. Wist, J Svartberg, T Wilsgaard, and R. Bremnes Components of the metabolic syndrome in long-term survivors of testicular cancer Ann. Onc., February 1, 2007; 18(2): 241 - 248. [Abstract] [Full Text] [PDF]

				C. B. Granger Prediction and Prevention of Chemotherapy-Induced Cardiomyopathy: Can It Be Done? Circulation, December 5, 2006; 114(23): 2432 - 2433. [Full Text] [PDF]

				D. Cardinale, G. Lamantia, and C. M. Cipolla Troponin I and Cardiovascular Risk Stratification in Patients With Testicular Cancer J. Clin. Oncol., July 20, 2006; 24(21): 3508 - 3508. [Full Text] [PDF]

				S. Kohli and M. Kohli Acute Chemotherapy-Induced Cardiovascular Changes in Patients With Testicular Cancer: Are There Implications for Blood Pressure Management in Patients Receiving Chemotherapy? J. Clin. Oncol., May 20, 2006; 24(15): 2399 - 2399. [Full Text] [PDF]